Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction therapy followed by surgery, postoperative concurrent chemoradiotherapy, and maintenance therapy for stage III borderline resectable or unresectable NSCLC
ChiCTR2600131238Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Sep 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin, paclitaxel and pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Disease-free survival. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
carboplatinpaclitaxelpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600131238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131238.